Vaxcyte, Inc. (NASDAQ:PCVX) Receives Average Rating of “Moderate Buy” from Analysts

Vaxcyte, Inc. (NASDAQ:PCVX) has earned a consensus rating of “Moderate Buy” from the eight brokerages that are covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, five have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $106.25.

A number of equities research analysts recently issued reports on the company. Cowen reissued a “buy” rating on shares of Vaxcyte in a research report on Thursday, August 7th. The Goldman Sachs Group assumed coverage on Vaxcyte in a research report on Friday, September 12th. They set a “neutral” rating and a $38.00 price target on the stock. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Vaxcyte in a research report on Tuesday.

Vaxcyte Trading Down 2.2%

Vaxcyte stock opened at $42.85 on Wednesday. Vaxcyte has a 12 month low of $27.66 and a 12 month high of $118.62. The stock’s 50 day moving average is $33.86 and its 200-day moving average is $33.54. The company has a market capitalization of $5.56 billion, a price-to-earnings ratio of -10.43 and a beta of 1.12.

Vaxcyte (NASDAQ:PCVX) last posted its earnings results on Wednesday, August 6th. The company reported ($1.22) EPS for the quarter, missing the consensus estimate of ($1.12) by ($0.10). During the same quarter in the prior year, the business earned ($1.10) earnings per share. As a group, equities research analysts predict that Vaxcyte will post -4.21 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Vaxcyte

Large investors have recently added to or reduced their stakes in the stock. Nisa Investment Advisors LLC boosted its holdings in shares of Vaxcyte by 10.9% in the 1st quarter. Nisa Investment Advisors LLC now owns 2,977 shares of the company’s stock valued at $112,000 after purchasing an additional 293 shares in the last quarter. Avior Wealth Management LLC boosted its holdings in shares of Vaxcyte by 5.3% in the 1st quarter. Avior Wealth Management LLC now owns 6,799 shares of the company’s stock valued at $257,000 after purchasing an additional 343 shares in the last quarter. HighVista Strategies LLC boosted its holdings in shares of Vaxcyte by 1.1% in the 2nd quarter. HighVista Strategies LLC now owns 33,457 shares of the company’s stock valued at $1,088,000 after purchasing an additional 355 shares in the last quarter. US Bancorp DE boosted its holdings in shares of Vaxcyte by 7.2% in the 1st quarter. US Bancorp DE now owns 5,344 shares of the company’s stock valued at $202,000 after purchasing an additional 357 shares in the last quarter. Finally, Xponance Inc. boosted its holdings in shares of Vaxcyte by 4.7% in the 1st quarter. Xponance Inc. now owns 9,320 shares of the company’s stock valued at $352,000 after purchasing an additional 415 shares in the last quarter. Institutional investors and hedge funds own 96.78% of the company’s stock.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.